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Abstract: High-fat and/or high-carbohydrate diets may predispose to several metabolic 
disturbances including liver fatty infiltration (hepatosteatosis) or be associated with   
necro-inflammation and fibrosis (steatohepatitis). Several studies have emphasized the 
hepatoprotective effect of some natural agents. In this study, we investigated the potential 
therapeutic effects of the treatment with emodin, an anthraquinone derivative with   
anti-oxidant and anti-cancer abilities, in rats developing diet-induced hepatosteatosis and 
steatohepatitis. Sprague-Dawley rats were fed a standard diet (SD) for 15 weeks, or a   
high-fat/high-fructose diet (HFD/HF). After 5 weeks, emodin was added to the drinking 
water of some of the SD and HFD/HF rats. The experiment ended after an additional   
10 weeks. Emodin-treated HFD/HF rats were protected from hepatosteatosis and metabolic 
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derangements usually observed in HFD/HF animals. Furthermore, emodin exerted   
anti-inflammatory activity by inhibiting the HFD/HF-induced increase of tumor necrosis 
factor (TNF)-α. Emodin also affected the hepatocytes glutathione homeostasis and levels 
of the HFD/HF-induced increase of glutathionylated/phosphorylated phosphatase and 
tensin homolog (PTEN). In conclusion, we demonstrated that a natural agent such as 
emodin can prevent hepatosteatosis, preserving liver from pro-inflammatory and   
pro-oxidant damage caused by HFD/HF diet. These findings are promising, proposing 
emodin as a possible hindrance to progression of hepatosteatosis into steatohepatitis. 
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1. Introduction 
Hepatosteatosis or simple fatty liver is characterized by accumulation of fat in liver cells. There are 
several different causes of hepatosteatosis, including chronic alcohol consumption, B and C viral 
hepatitis, type 2 diabetes, obesity and some metabolic aberrations [1,2]. Actually, nonalcoholic fatty 
liver disease (NAFLD) is considered the most prevalent form of hepatosteatosis associated with 
obesity and metabolic syndrome [3,4]. During the last 20 years, NAFLD has reached worrying 
proportion involving 20–30% of adults and 3–10% of children in Western countries [5]. NAFLD 
genesis is multifactorial and comprises different patterns of liver injuries including simple 
hepatosteatosis alone or in combination with nonalcoholic steatohepatitis (NASH), with or without 
fibrosis [6].  
In recent years, many studies have provided new insights explaining potential mechanisms 
responsible for the switch from hepatosteatosis to NASH. So far it has been established that NAFLD 
pathogenesis and progression depends on different “hits” and it has been shown that the genetic 
makeup and dietary intake play key roles as leading factors [7,8]. A working model [9] has been 
proposed consisting of two sequential “hits”, the first conducting to the hepatic steatosis and the 
second towards the hepatic necro-inflammation determining the NASH condition and possibly fibrosis. 
Firstly, the insulin resistance (IR), and/or the derangement of fatty acid metabolism (de novo 
lipogenesis, lower beta oxidation, impairment of triglyceride clearance and the diminished export of 
very-low-density lipoprotein), leads to hepatic fat accumulation and increased liver sensitivity to other 
possible subsequent hits [3,10]. Followed by a still largely unknown mechanism, multifactorial 
complex interactions have been described as responsible for the “second hit” leading to the more 
advanced form of NASH which can possibly predispose to cirrhosis [11,12]. This further hit includes 
oxidative stress, lipid peroxidation, imbalance of inflammatory cytokines and adipokines and 
augmentation of pathogen- or damage-associated molecular patterns [13–15]. 
Nowadays the intervention against the NAFLD status encompasses two different and complementary 
directions: lifestyle changes and/or pharmacological treatment against specific hits potentially involved 
in NAFLD pathogenesis (i.e., insulin resistance and oxidative stress) [16]. In the last decade many 
noteworthy efforts have been made for ameliorating the hepatic damage in NAFLD. It has been 
extensively demonstrated that metformin, vitamin E or placebo treatments do not have positive effects Int. J. Mol. Sci. 2012, 13 2278 
 
 
on liver injury although vitamin E is able to improve the hepatocellular ballooning degeneration [17].  
The current known targets for treatment of NAFLD are limited in number and are not even 
sufficiently defined and a breakthrough for new tolerated and efficient compounds is needed [16]. In 
fact, many studies are aimed at testing the effect of natural agents on NAFLD evolution [18–25]. It has 
been proven that Silibinin (silybin), a polyphenolic molecule constituent of silymarin (a flavonolignan 
extracted from Silibum marianum), has anti-oxidant and hepatoprotective effects [20]. Moreover, it 
protects against cirrhosis, decreases fibrosis if complemented to vitamin E and phospholipids and 
decreases both insulin resistance and plasma markers of liver fibrosis in NAFLD patients [21]. 
Curcumin, a polyphenol and an active component of turmeric (Curcuma longa), is another natural 
compound investigated by several laboratories. Clinical studies showed a protective action against 
fructose-induced hepatic steatosis by improving inflammation, hyperlipidemia, reducing insulin 
resistance and interrupting leptin signaling [22–24]. Interestingly, it has been demonstrated that 
emodin (1,3,8-trihydroxy-6-methylanthraquinone), which is an active herbal component traditionally 
used in China for treating a variety of diseases, might have a role in the disease regression in  
NAFLD-induced rats. In fact, emodin significantly decreased the body weight, liver index, serum 
activities of ALT, blood lipids, hepatic triglyceride and considerably improved the hepatic histology 
features [25]. Despite these encouraging results, to date no further thoughtful studies have been made 
to understand mechanisms and reliability of emodin in NAFLD models. 
The wide diffusion of NAFLD in developed countries and its close correlation with cirrhosis, place 
the study of both prevention and therapeutic approaches, based on natural safe and efficient agents, in 
a central position of interest. Thus, in this study we attempted to investigate the potential preventive 
properties of emodin in a diet-induced hepatosteatosis in rats. 
2. Results and Discussion 
2.1. Effects of Five Weeks HFD/HF Diet on Rats 
Nowadays the pivotal role of fructose in NAFLD pathogenesis is widely recognized [26,27]. In fact, 
the excessive fructose intake may enhance the synthesis of triacylglycerols that accumulate in the liver 
causing hepatosteatosis, and trigger the inflammatory response that lead to NASH [28,29]. Noteworthy, 
recently Kohli et al. [30] developed a model of NAFLD that well resembled human disease by using 
an animal model fed with high-fructose medium-chain-trans-fat diet. Moreover, more recently we 
developed another interesting model of NAFLD that combined high fat diet with high 30%   
fructose-enriched drinking water [31]. In this study, we used the same high fat/high fructose (HFD/HF) 
dietetic regimen compared to standard diet (SD) for 5 and 15 weeks. At the end of the 5th week of 
treatment, SD and HFD/HF animal body weight data was recorded. At the same time, blood samples 
were collected from caudal vein to perform metabolic analysis. As shown in Table 1, animal body 
weight displayed an increase of about 19% compared to the beginning of diet protocols. However, no 
sign of NAFLD was already evident in HFD/HF, as shown by the absence of statistically relevant 
changes in body weight and metabolic parameters between the two groups of treatment. These results 
suggest that rats may accumulate significant traits of hepatosteatosis if the treatment with HFD/HF diet 
is extended for a longer period of time. In fact, as we recently demonstrated, a 3 months treatment with Int. J. Mol. Sci. 2012, 13 2279 
 
 
HFD/HF diet is necessary to develop hepatosteatosis and NASH in Sprague-Dawley rats [31].  
Table 1. Body weight and biochemical parameters at 5th week. 
Parameters SD  HFD/HF 
Body weight (g)  140.8 ± 25.8  143.6 ± 23.2 
Triglycerides (mg/dL)  92 ± 13.5  104 ± 19.4 
Total cholesterol (mg/dL)  39.5 ± 5.8  44.0 ± 6.2 
ALT (U/L)  22.3 ± 3.6  25.4 ± 4.5 
Glucose (mg/dL)  65.0 ± 7.5  73.4 ± 10.1 
Insulin (ng/mL)  0.23 ± 0.04  0.25 ± 0.03 
HOMA-IR  0.92 ± 0.08  1.13 ± 0.15 
Values are means ± SD. 
2.2. Effects of Emodin on Body Weight, Liver Weight and Metabolic Parameters in HFD/HF Rats 
Dong et al. [25], as reported above, demonstrated the emodin therapeutic action in Sprague-Dawley 
rats fed with high-caloric diet for 12 weeks. Whereas, here, we evaluated the preventive effect of emodin 
(40 mg/kg/day) in 5 weeks pre-treated rats that received the treatment with SD or HFD/HF for an 
additional 10 weeks. Data collected from these animals were compared with two groups subjected to SD 
or HFD/HF without addition of emodin. At the end of treatments, the body and liver weight, and liver 
index (liver weight/body weight × 100), were evaluated. As reported in Table 2, in HDF/HF group the 
weight patterns were significantly increased compared with those in the SD group (P < 0.05). 
Interestingly, in HFD/HF animals emodin treatment caused a slight increase of body weight (P < 0.05), 
that was counteracted by a significant decrease of liver weight and index (P < 0.01). As expected, 
HFD/HF diet resulted in a significant rise in plasma levels of ALT, triglycerides, insulin and glucose, and 
HOMA-IR (P < 0.01). Interestingly, emodin treatment in HFD/HF group considerably reduced 
metabolic parameters bringing their values at levels very similar to those observed in SD animals (see 
Table 2). 
2.3. Hepatoprotective and Anti-Inflammatory Effects of Emodin in HFD/HF Rats 
Currently, the diagnosis of NAFLD, and particularly the identification of steatohepatitis, is based on 
the histological evaluation of the liver biopsy [6]. Therefore, liver histology, despite its limitations, is 
the most reliable method to assess grading and staging of all histological features that characterize 
NASH both in humans and animal models [32,33]. Here, we analyzed the histological pattern of 
NAFLD by Hematoxylin-Eosin (H-E) staining. Liver of HFD/HF animals showed typical 
microvacuolar and macrovacuolar steatosis, ballooning, and some inflammatory cells, confirming the 
successful establishment of the animal model. With the emodin treatment HFD/HF animals displayed 
reduced cytological steatosis and ballooning, and a complete absence of inflammatory cells (Figure 1). 
These results are in agreement with previous studies demonstrating the hepatoprotective role of emodin 
both in the case of hepatosteatosis and in other liver diseases [34–36]. Emodin exerts multiple effects, 
including anti-proliferative, anti-cancer, anti-inflammatory and hepatoprotective activities [37–39]. Int. J. Mol. Sci. 2012, 13 2280 
 
 
Emodin has also been reported to reduce serum hyaluronic acid, laminin expression, hepatic levels of 
hydroxyproline and the degree of liver fibrosis [40]. 
Table 2. Body weight and biochemical parameters after emodin treatments for 10 weeks. 
Parameters SD  HFD/HF  SD+emodin HFD/HF+emodin
Body weight (g)  295.6 ± 34.2  355.6 ± 28.7 *  308.1 ± 30.5  393.6 ± 31.4 † 
Liver weight (g)  11.2 ± 1.3  15.2 ± 1.5 *  12.0 ± 0.5  12.4 ± 0.9 † 
Liver weight/Body weight  3.7 ± 0.11  4.27 ± 0.09 *  3.8 ± 0.19  3.2 ± 0.2 ‡ 
Triglycerides (mg/dL)  105.1 ± 18.6  138.0 ± 16.3 **  110.4 ± 13.1  109.4 ± 15.7 ‡ 
Total cholesterol (mg/dL)  45.7 ± 7.2  48.5 ± 8.1  39.9 ± 10.2  48.0 ± 12.3 
ALT (U/L)  25.2 ± 5.0  37.4 ± 3.9 **  26.0 ± 4.4  25.9 ± 5.8 ‡ 
Glucose (mg/dL)  69.4 ± 4.4  81.9 ± 5.7 **  68.3 ± 7.2  70.8 ± 9.6 ‡ 
Insulin (ng/mL)  0.24 ± 0.05  0.41 ± 0.09 **  0.25 ± 0.07  0.26 ± 0.03 ‡ 
HOMA-IR  1.02 ± 0.05  2.07 ± 0.18 **  1.05 ± 0.06  1.13 ± 0.19 ‡ 
Values are means ± SD. * P = 0.05, ** P < 0.01, vs. SD group; Values are means ± SD. † P = 0.05,  
‡ P < 0.01, vs. HFD/HF group. 
Figure 1. Histological changes of rat liver in each group stained by H-E (Magnification 200×).  
 
In this, study we also evaluated the systemic anti-inflammatory properties of emodin by the analysis 
of plasma levels of two relevant pro-inflammatory cytokines in NAFLD, tumor necrosis factor   
(TNF)-α and interleukin 6 (IL6) [41]. Although, the increased hepatic expression of TNF-α and IL6 
has been described in NAFLD obese patients, changes and significance of the circulating levels of 
these cytokines still remain unclear [42,43]. Recently, it has been demonstrated that either high 
carbohydrate diet or high fat diet are able to increase plasma levels of TNF-α in mice [44]. In the 
present study, we examined the circulating levels of TNF-α and IL6 in all animal groups. As reported 
in Figure 2a and b, HFD/HF regimen induced a significant increase in the plasma levels of TNF-α with 
respect to the SD; whereas no significant differences in the IL6 plasma levels were found between the 
two groups. Interestingly, the treatment with emodin impeded the rise of plasma TNF-α, maintaining 
this circulating cytokine at levels similar to those observed in SD group.  
Anti-inflammatory activity of emodin has already been reported, but this study represents the first 
evidence demonstrating its potential preventive action on systemic inflammation occurring in NAFLD. Int. J. Mol. Sci. 2012, 13 2281 
 
 
Figure 2. Plasma levels of TNF-α (a) and IL6 (b) in all groups of treatment. Values are 
means ± SD. *** P < 0.001, vs. SD group. ‡ P < 0.01, vs. HFD/HF group. 
 
2.4. Emodin Promotes Recovery of Redox Status Imbalance in Primary Hepatocytes from HFD/HF Rats 
Glutathione is a tripeptide that exists in a reduced (GSH) and oxidized form (GSSG). The ratio 
between these two glutathione forms is fundamental for maintaining the redox status balance and 
important cellular functions, such as cell proliferation [45]. GSSG may also occur as protein-bound 
glutathione (ProSSG). ProSSG plays a pivotal role in the regulation of important regulatory proteins 
including NFκB and PTEN (glutathionylation) [46,47]. We recently demonstrated that HFD/HF diet 
was able to promote redox status imbalance particularly increasing the ratio between ProSSG and total 
GSH (Tot GSH = GSSG + GSH + ProSSG) in primary hepatocytes [48]. Here we confirmed this data 
and demonstrated that emodin treatment protects from the increment of ProSSG/Tot GSH ratio in 
primary hepatocytes isolated from HFD/HF (Figure 3a). These results corroborate the hypothesis of a 
strong anti-oxidant action of emodin on steatotic livers. Moreover, as in the previous published study [48], 
we found that HFD/HF diet caused an increment in phosphorylation/glutathionylation of hepatic PTEN, 
that is consistent with the inhibition of its activity; here we assayed if emodin was able to protect 
primary hepatocytes from PTEN phosphorylation/glutathionylation. As reported in Figure 3b, emodin 
treatment preserves PTEN either from phosphorylation and glutathionylation. 
A quantity of data has shown that the alterations of PTEN expression and activity are related   
with liver disorders and its deregulation plays a key role both in hepatic insulin sensitivity and the 
onset of steatosis, steatohepatitis and fibrosis [49]. Moreover PTEN regulates the PI3K/Akt signaling  
pathways [50] and Akt is differently involved in glucose homeostasis and diabetes [51]. In this study 
we have demonstrated that the increased PTEN phosphorylation/glutathionylation in HFD/HF diet  
rats may be counteracted by emodin treatment. The significance of these results is intriguing since  
the recovery of PTEN activation should explain the improved effect on insulin resistance in   
emodin-treated HFD/HF rats. Therefore, in the future, it would be interesting to study the activity of 
PTEN before and after the emodin treatment. Moreover, it would be worth investigating a possible Akt 
role in the mechanism regulating the positive effect of emodin with regard to the disrupted glucose 
homeostasis in NAFLD rat model. 
b a Int. J. Mol. Sci. 2012, 13 2282 
 
 
Figure 3. (a) ProSSG/Tot GSH ratios were reported. Histograms are the mean value ± S.D. 
*** P < 0.001, vs. SD group. ‡ P < 0.01, vs. HFD/HF group; (b) Western blotting of total, 
phosphorylated and glutathionylated PTEN in primary hepatocytes isolated from livers of 
each group of treatment. 
 
2.5. Emodin Protects HFD/HF Primary Hepatocytes Rats from Further Oxidative Stress Damage 
Hepatosteatosis may evolve to NASH with fibrosis that destructs liver tissue integrity and cell 
homeostasis. This phenomenon occurs by a pool of secondary hits, among which the most relevant is 
the oxidative stress [13]. Our hypothesis is that preventive treatment with emodin not only may   
protect HFD/HF rats from hepatosteatosis, but it may also induce an anti-oxidant stable reaction of 
hepatocytes against further oxidative stress damage and predispose liver cells to a better response to 
additional anti-oxidant conventional drugs (e.g., N-acetylcysteine and α-tocopherol). To assess this 
hypothesis, we isolated primary hepatocytes from rats treated with SD, or HFD/HF regimen with or 
without emodin. These cells were cultured for 24 h in the presence or the absence of the following 
treatments: 500 µM hydrogen peroxide (H2O2) or 1 mM N-acetylcysteine (NAC). At the end of the 
experiment, we collected cells to evaluate ProSSG/Tot GSH ratio and cell viability. As shown in  
Figure 4a, the treatment with H2O2 dramatically increased ProSSG/Tot GSH ratio in hepatocytes from 
HFD/HF rats, but this effect was significantly reduced in hepatocytes from emodin-treated HFD/HF 
animals. On the other hand, in hepatocytes from HFD/HF rats, the treatment with NAC caused a 
relevant decrease of ProSSG/Tot GSH ratio that was enhanced by the concomitant presence of emodin 
in animals’ in vivo treatment. 
Finally, cell viability results indicated that hepatocytes from HFD/HF animals displayed a reduced 
cell viability, after 24 h culture, compared with SD-derived hepatocytes (Figure 4b). However, in 
hepatocytes from HFD/HF, this reduced viability was significantly counteracted by NAC treatment 
and retrieved even more if the hepatocytes were derived from emodin treated HFD/HF rats as 
described above. 
Altogether, these findings indicate that HFD/HF regimen may profoundly alter oxidative stress 
response and cell homeostasis of hepatocytes, but these effects are counteracted by the preventive 
treatment with emodin. 
a  b Int. J. Mol. Sci. 2012, 13 2283 
 
 
Figure 4. (a) ProSSG/Tot GSH ratios were reported as fold induction; (b) Cell viability at 
24 h was evaluated by a neutral red assay and reported as percentage compared with the 
control (SD). Histograms are the mean value ± S.D. *** P < 0.001; ‡ and § P < 0.01,  
# P < 0.05. 
 
3. Experimental Section  
3.1. Animals and Primary Hepatocytes 
Twenty-four male Sprague–Dawley rats (120–140 g) were obtained from Harlan Italy (San Pietro al 
Natisone, UD, Italy). The animals received treatment in agreement with the European guidelines of the 
local committee for animal care and welfare. The animals used in this study were part of a large 
experimental protocol approved by Italian Ministry of Health. They were located in plastic cages   
under standard conditions with free access to water and food, at the Certified Animal Facility of the 
University of Rome, “La Sapienza”. The animals were fed with standard rat chow for 5 days then 
equally grouped based on two different dietetic regimens: a standard diet (SD) and a high-fat/high-fructose 
diet (HFD/HF). SD contained 5% of energy derived from fat, 18% from proteins, and 77% from 
a 
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carbohydrates (3.3 kcal/g), while HFD/HF contained 58% of energy derived from fat, 18% from 
protein, and 24% from carbohydrates (5.6 kcal/g; Laboratorio Dottori Piccioni, Gessate Milano, Italy); 
plusfructose (30%) that was added to the drinking water. After 5 weeks half of SD and HFD/HF were 
treated with emodin (40 mg/kg/day) from Sigma-Aldrich, Milan, Italy. Fluid and food intake were 
assessed every two-days at the replacement. We found no significant differences between consumption 
of food and water among the groups. 
Randomly after 6 h fasting, from each group of animal, liver tissues were taken for biochemistry 
and histology. Further, from each group primary hepatocytes have been isolated using a perfusive 
method as previously described [52]. Briefly, the rats were anesthetized by intraperitoneal administration 
of sodium pentobarbital (5 mg/100 g body weight). The liver was perfused firstly with a calcium-free 
Hank’s balanced salt solution containing 2% BSA and 0.6 mM ethyleneglycotetraacetic acid, and 
secondly with Hank’s solution containing 4 mM calcium chloride and 0.04% collagenase. Liver cells 
were released into a Krebs–Henseleit buffer with 2% BSA. The hepatocytes were seeded on   
collagen-coated plates at density between 1.5 × 10
4 and 3 × 10
4 /cm
2.  After 24 h from plating 
hepatocytes from SD, HFD/FD, SD + Emodin, HFD/HF + Emodin animals were subjected to 
following treatments: 10 μL PBS (NT) or N-acetylcysteine 1mM (NAC) or H2O2 500M (H2O2). 
Hepatocytes were harvested 24 h later, centrifuged and collected for the experiments. 
3.2. Biochemical Determinations and Inflammatory Markers 
Blood samples obtained from caudal vein after 6 h fasting were collected in sterile glass tubes 
containing 0.15% EDTA. Blood samples were centrifuged at 3000 for 15 min to obtain plasma. Plasma 
samples were immediately used to perform enzymatic and photocolorimetric assay to determine the 
levels of alanine aminotransferase (ALT), triglycerides, total cholesterol, glucose and insulin. 
Enzymatic and colorimetric assays were performed using standard procedures as indicated by kits 
purchased from different companies: ALT assay kit from Randox Laboratories Ltd (Antrim, UK), 
triglycerides and cholesterol assay kits from Cayman Chemical (Ann Arbor, MI, USA), glucose assay 
kit from Abcam Inc (Cambridge, MA, USA), and rat insulin enzyme immunoassay kit from SPI-BIO 
(France). At 14 weeks, insulin resistance was calculated according to the homeostasis model assessment 
of insulin resistance (HOMA-IR) calculation: fasting plasma insulin (μU/mL) × fasting plasma glucose 
(mmol/L)/22.5. ELISA-based kits were used to assay the circulating levels TNF-α (Peprotech, Rocky 
Hill, New Jersey, USA) and IL6 (R&D Systems, Abingdon, UK). 
3.3. Immunohistochemistry 
Liver was fixed in 4% buffered formalin and embedded in paraffin. A measure of 3–5 μm sections 
were stained with haematoxylin and eosin (Bio-Optica, Milan, Italy). Then the specimens were 
evaluated under 10 × 20 light microscopic fields. 
3.4. High-Performance Liquid Chromatography of GSH 
The tissues and primary hepatocytes from liver mouse model NASH diet-induced or NASH   
diet-induced treated with Emodin were sonicated (Sonics Vibra Cell, Sonics & Material Inc., Newtown, Int. J. Mol. Sci. 2012, 13 2285 
 
 
CT, USA), three times for 2 s in 0.1 mL of 0.1 M potassium phosphate buffer (pH 7.2). Following the 
sonication levels of total (GSH Tot), reduced (GSH), oxidized (GSSG) and protein-bound (ProSSG) 
glutathione were analyzed by HPLC. HPLC equipment and conditions for analyzing the several forms 
of glutathione have been reported [53]. 
3.5. Immunoprecipitation and Western Blotting  
Liver tissues were lysed in ice-cold Ripa buffer containing 50 mM Tris pH 7.5, 150 mM NaCl,  
1% Triton X-100, 1 mM EGTA, 1% sodium deoxycholate and phosphatases 10% cocktail protease 
inhibitors. For the immunoprecipitation protocol of the glutathionylated proteins see previous 
published work [46]. Then protein extracts were resolved on 10–12.5% SDS-PAGE, transferred and 
immobilized onto nitrocellulose membrane (Amersham, Germany), blocked with 5% nonfat dry milk 
and incubated with appropriate primary and secondary antibodies. The anti-PTEN, anti-pPTEN, primary 
antibodies were purchased from Santa Cruz Biotech (CA, USA). Immunoblots were detected with  
the ECL system (Amersham) and the relative intensities of the specific bands were determined by 
densitometric analysis and referring to beta-actin protein expression. 
3.6. Cell Viability  
Cell viability was determined by a simple vital stain method that evaluates the accumulation of the 
neutral red dye in the lysosomes of viable, uninjured cells [54]. The simple vital Neutral red   
(Sigma-Aldrich) was dissolved in culture medium and added to cells for 1 h. The pH of the neutral red 
solution was adjusted in all the experiments to 6.35 with the addition of 1 M KH2PO4. Then, cells were 
washed thrice with PBS, and 1 mL of elution medium (EtOH/AcCOOH, 50%/1%) was added followed 
by gentle shaking for about 10 minutes to obtain the complete dissolution. Measures were acquired 
with spectrophotometer at 540-nm of absorbance. 
3.7. Statistical Analysis 
The results are reported as means ± SD. for at least four independent experiments. Statistical 
differences were determined by Student’s t test considering P < 0.05 as statistically significant. 
4. Conclusions  
In summary, in this study we reported for the first time the preventive effect of emodin on 
hepatosteatosis-dependent metabolic derangement and liver cell injury. In particular, our results 
demonstrated that emodin was able to protect rats, treated with high fat/high fructose diet, from insulin 
resistance, hypertriglyceridaemia, histological damage, systemic necro-inflammation, and oxidative stress. 
Furthermore, interestingly, we demonstrated that emodin treatment conferred to HFD/HF hepatocytes an 
important defense from additional oxidative stress, and an improved ability to react to classical   
anti-oxidant agents. Our data suggested that PTEN could be a target of emodin, but the full 
comprehension of the existing molecular mechanisms of this natural agent requires further study.  Int. J. Mol. Sci. 2012, 13 2286 
 
 
In conclusion, all these findings suggest the use of emodin, not only as a potential preventive agent 
in NAFLD diet-induced and a promising agent for hampering the progression to NASH, but also as a 
natural coadjuvant of the more classical antioxidant therapy. 
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